Not Tagged
Not Tagged
['brca', 'prostate']
david olmos, mbbs, msc, phd, discusses research presented at the asco 2023 annual meeting assessing outcomes with first-line novel hormonal therapy or taxane therapy in metastatic castration-resistant prostate cancer based on patients' brca/hrr status. 
Here are the news from the leading urological communities in the world (EAU,AUA,ICS,UAA,RAU and others)